Table SI. *Proportional hazard regression, supportive analyses (full analysis set (FAS), per protocol set (PPS))*

		FAS			PPS		
Analysis	Covariate	*p*-value	Hazard ratio	95% CI of hazard ratio	*p*-value	Hazard ratio	95% CI of hazard ratio
Unadjusted	Test cream	0.0046	0.609	0.431, 0.858	0.0127	0.643	0.454, 0.910
Severity	Test cream	0.0053	0.610	0.431, 0.863	0.0134	0.642	0.452, 0.912
	Historic AD	0.3331	1.065	0.937, 1.210	0.4064	1.056	0.929, 1.201
SCORAD	Test cream	0.0133	0.643	0.453, 0.912	0.0302	0.677	0.476, 0.963
	Screening SCORAD	0.0136	1.018	1.004, 1.032	0.0221	1.017	1.002, 1.031

AD: atopic dermatitis; SCORAD: SCORing atopic dermatitis; 95% CI: 95% confidence interval.

Table SII. *Time to relapse of atopic eczema (days) Kaplan–Meier estimate of median (full analysis set (FAS), per protocol set (PPS))*

	FAS[a]			PPS[b]		
	Test cream	Reference cream	Total	Test cream	Reference cream	Total
Observations, *n*	85	82	167	83	79	162
Censored observations, *n* (%)	23 (27.1)	9 (11.0)	32 (19.2)	21 (25.3)	8 (10.1)	29 (17.9)
Median time to relapse, days	22.0	15.0	18.0	22.0	15.0	17.5

p-value from log-rank test: [a]0.0129; [b]0.0311.

Table SIII. *Absolute and relative risk (full analysis set (FAS), per protocol set (PPS))*

	FAS			PPS		
	Test cream	Reference cream		Test cream	Reference cream	
Day 28						
Conditional probability of failure (%)	61.2	74.8		62.7	74.7	
Absolute risk reduction (%)			13.7			12.0
Relative risk reduction (%)			18.3			16.1
Relative risk			1.22			1.19
Day 180						
Conditional probability of failure (%)	76.1	90.1		77.0	90.4	
Absolute risk reduction (%)			14.0			13.4
Relative risk reduction (%)			15.6			14.8
Relative risk			1.18			1.17

Table SIV. *Summary of adverse events (AE) (safety population)*

	Test cream (*n* = 87) *n* (%)	Reference cream (*n* = 85) *n* (%)	Total (*n* = 172) *n* (%)
Patients	87 (100)	85 (100)	172 (100)
Unique adverse events[a]	83	75	158
Adverse events	102	90	192
Patients with at least 1 adverse event	48 (55)	44 (52)	92 (53)
Unique serious adverse events[a]	0	1	1
Serious adverse events	0	1	1
Patients with at least 1 serious adverse event	0	1 (1)	1 (1)
Unique related adverse events[a]	6	6	12
Related adverse events	6	6	12
Patients with at least 1 related adverse event	5 (6)	5 (6)	10 (6)
Patients with at least 1 adverse event leading to discontinuation of study drug	3 (3)	5 (6)	8 (5)

[a]Unique adverse event: events with the same preferred term are counted only once within each patient.